What is the first-line pharmacological treatment for new-onset type 2 diabetes?

References

1. [1]

   Uhl S, Choure A, Rouse B et al.. “Effectiveness of Continuous Glucose Monitoring on Metrics of Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37987208 ↗

   L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
2. [2]

   Badve SV, Bilal A, Lee MMY et al.. “Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.” The lancet. Diabetes & endocrinology (2024). PMID: 39608381 ↗

   L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
3. [3]

   Apperloo EM, Neuen BL, Fletcher RA et al.. “Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.” The lancet. Diabetes & endocrinology (2024). PMID: 38991584 ↗

   L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
4. [4]

   Lingvay I, Capehorn MS, Catarig AM et al.. “Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32827435 ↗

   L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
5. [5]

   Kim H, Bae S, Yoon HY et al.. “Association of the SLC47A1 Gene Variant With Responses to Metformin Monotherapy in Drug-naive Patients With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35639991 ↗

   L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
6. [6]

   Zhou Y, Huang Y, Ji X et al.. “Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31822895 ↗

   L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
7. [7]

   Khunti K, Seidu S, Kunutsor S et al.. “Association Between Adherence to Pharmacotherapy and Outcomes in Type 2 Diabetes: A Meta-analysis.” Diabetes care (2017). PMID: 28801474 ↗

   L2SR_OBSCited in: Bottom Line, Current Evidence and Standard
8. [8]

   Rodbard HW, Lingvay I, Reed J et al.. “Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29688502 ↗

   L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
9. [9]

   Frias JP, De Block C, Brown K et al.. “Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).” The Journal of clinical endocrinology and metabolism (2024). PMID: 38252888 ↗

   L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
10. [10]

    Wittert GA, Robledo KP, Handelsman DJ et al.. “Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39928571 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
11. [11]

    Lingvay I, Bache JK, Desouza CV et al.. “Efficacy and Hypoglycemia Profile of Once-weekly Insulin Icodec vs Once-daily Comparators Across Demographic Subgroups.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40102962 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
12. [12]

    Whyte MB, Shojaee-Moradie F, Sharaf SE et al.. “Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30215735 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
13. [13]

    Shehadeh N, Galassetti P, Iqbal N et al.. “Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children With Type 2 Diabetes (T2NOW Follow-Up).” The Journal of clinical endocrinology and metabolism (2025). PMID: 39446459 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
14. [14]

    Ahmann AJ, Capehorn M, Charpentier G et al.. “Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.” Diabetes care (2017). PMID: 29246950 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
15. [15]

    Rodbard HW, Rosenstock J, Canani LH et al.. “Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.” Diabetes care (2019). PMID: 31530666 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
16. [16]

    Nauck MA, Petrie JR, Sesti G et al.. “A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.” Diabetes care (2015). PMID: 26358288 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
17. [17]

    Hadjadj S, Rosenstock J, Meinicke T et al.. “Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.” Diabetes care (2016). PMID: 27493136 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
18. [18]

    Zhang B, Cheng Z, Chen J et al.. “Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.” Diabetes care (2024). PMID: 37943529 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
19. [19]

    Halden TAS, Kvitne KE, Midtvedt K et al.. “Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.” Diabetes care (2019). PMID: 30862658 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
20. [20]

    Kuchay MS, Krishan S, Mishra SK et al.. “Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).” Diabetes care (2018). PMID: 29895557 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
21. [21]

    Garvey WT, Birkenfeld AL, Dicker D et al.. “Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.” Diabetes care (2020). PMID: 32139381 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
22. [22]

    Zinman B, Aroda VR, Buse JB et al.. “Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.” Diabetes care (2019). PMID: 31530667 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
23. [23]

    Ferreira JP, Oliveira AC, Saraiva FA et al.. “Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis.” European journal of endocrinology (2021). PMID: 33769961 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
24. [24]

    Stomby A, Otten J, Ryberg M et al.. “Diet-induced weight loss alters hepatic glucocorticoid metabolism in type 2 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32069218 ↗

    L2RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
25. [25]

    Ajjan RA, Hensor EMA, Del Galdo F et al.. “Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomized controlled trial.” European journal of endocrinology (2022). PMID: 35113805 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
26. [26]

    van Raalte DH, Bunck MC, Smits MM et al.. “Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.” European journal of endocrinology (2016). PMID: 27466218 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
27. [27]

    Smits MM, Tonneijck L, Muskiet MH et al.. “Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.” European journal of endocrinology (2016). PMID: 27777261 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
28. [28]

    Lemieux P, Weisnagel SJ, Caron AZ et al.. “Effects of 6-month vitamin D supplementation on insulin sensitivity and secretion: a randomised, placebo-controlled trial.” European journal of endocrinology (2019). PMID: 31344685 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
29. [29]

    Kristensen SL, Rørth R, Jhund PS et al.. “Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.” The lancet. Diabetes & endocrinology (2019). PMID: 31422062 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
30. [30]

    Sorli C, Harashima SI, Tsoukas GM et al.. “Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.” The lancet. Diabetes & endocrinology (2017). PMID: 28110911 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
31. [31]

    Kadowaki T, Isendahl J, Khalid U et al.. “Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.” The lancet. Diabetes & endocrinology (2022). PMID: 35131037 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
32. [32]

    Mu Y, Bao X, Eliaschewitz FG et al.. “Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.” The lancet. Diabetes & endocrinology (2024). PMID: 38330988 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
33. [33]

    Gastaldelli A, Cusi K, Fernández Landó L et al.. “Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.” The lancet. Diabetes & endocrinology (2022). PMID: 35468325 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
34. [34]

    le Roux CW, Steen O, Lucas KJ et al.. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” The lancet. Diabetes & endocrinology (2024). PMID: 38330987 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
35. [35]

    Heise T, Mari A, DeVries JH et al.. “Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.” The lancet. Diabetes & endocrinology (2022). PMID: 35468322 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
36. [36]

    Wheeler DC, Stefánsson BV, Jongs N et al.. “Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.” The lancet. Diabetes & endocrinology (2021). PMID: 33338413 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
37. [37]

    Bakris GL, Agarwal R, Anker SD et al.. “Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.” The New England journal of medicine (2020). PMID: 33264825 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
38. [38]

    Marso SP, Daniels GH, Brown-Frandsen K et al.. “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” The New England journal of medicine (2016). PMID: 27295427 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
39. [39]

    Bi Y, Li M, Liu Y et al.. “Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.” The New England journal of medicine (2024). PMID: 39555827 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
40. [40]

    Davies MJ, Bajaj HS, Broholm C et al.. “Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40544432 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
41. [41]

    Nathan DM, Lachin JM, Balasubramanyam A et al.. “Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.” The New England journal of medicine (2022). PMID: 36129996 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
42. [42]

    Pittas AG, Dawson-Hughes B, Sheehan P et al.. “Vitamin D Supplementation and Prevention of Type 2 Diabetes.” The New England journal of medicine (2019). PMID: 31173679 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
43. [43]

    Kudva YC, Raghinaru D, Lum JW et al.. “A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40105270 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
44. [44]

    Schauer PR, Bhatt DL, Kirwan JP et al.. “Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.” The New England journal of medicine (2017). PMID: 28199805 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
45. [45]

    Arslanian SA, Hannon T, Zeitler P et al.. “Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.” The New England journal of medicine (2022). PMID: 35658022 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
46. [46]

    Steg PG, Bhatt DL, Simon T et al.. “Ticagrelor in Patients with Stable Coronary Disease and Diabetes.” The New England journal of medicine (2019). PMID: 31475798 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
47. [47]

    Green CJ, Marjot T, Walsby-Tickle J et al.. “Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis.” European journal of endocrinology (2022). PMID: 35038311 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard
48. [48]

    Karagiannis T, Avgerinos I, Liakos A et al.. “Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.” Diabetologia (2022). PMID: 35579691 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
49. [49]

    Davies M, Færch L, Jeppesen OK et al.. “Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.” Lancet (London, England) (2021). PMID: 33667417 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
50. [50]

    Garvey WT, Frias JP, Jastreboff AM et al.. “Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.” Lancet (London, England) (2023). PMID: 37385275 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
51. [51]

    Rosenstock J, Wysham C, Frías JP et al.. “Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.” Lancet (London, England) (2021). PMID: 34186022 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
52. [52]

    Bonaca MP, Catarig AM, Houlind K et al.. “Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.” Lancet (London, England) (2025). PMID: 40169145 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
53. [53]

    Rosenstock J, Frias J, Jastreboff AM et al.. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.” Lancet (London, England) (2023). PMID: 37385280 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
54. [54]

    Kosiborod MN, Deanfield J, Pratley R et al.. “Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.” Lancet (London, England) (2024). PMID: 39222642 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
55. [55]

    Armstrong MJ, Gaunt P, Aithal GP et al.. “Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.” Lancet (London, England) (2015). PMID: 26608256 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
56. [56]

    Frias JP, Deenadayalan S, Erichsen L et al.. “Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.” Lancet (London, England) (2023). PMID: 37364590 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
57. [57]

    Frias JP, Hsia S, Eyde S et al.. “Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.” Lancet (London, England) (2023). PMID: 37369232 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard, On the Horizon
58. [58]

    Hannon TS, Chao LC, Barrientos-Pérez M et al.. “Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet (London, England) (2025). PMID: 40975112 ↗

    L1RCTCited in: Bottom Line, Current Evidence and Standard
59. [59]

    Blüher M, Rosenstock J, Hoefler J et al.. “Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.” Diabetologia (2023). PMID: 38095657 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
60. [60]

    Lingvay I, Benamar M, Chen L et al.. “Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.” Diabetologia (2025). PMID: 39820580 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
61. [61]

    McCrimmon RJ, Catarig AM, Frias JP et al.. “Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.” Diabetologia (2020). PMID: 31897524 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
62. [62]

    van den Burg EL, Schoonakker MP, van Peet PG et al.. “Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial.” Diabetologia (2024). PMID: 38546821 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
63. [63]

    Wang W, Bain SC, Bian F et al.. “Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.” Diabetologia (2024). PMID: 38985162 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
64. [64]

    Ji L, Agesen RM, Bain SC et al.. “Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial.” Diabetologia (2024). PMID: 38985161 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
65. [65]

    Gao S, Zhang F, Xie X et al.. “Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trials.” Frontiers in endocrinology (2026). PMID: 42211460 ↗

    L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
66. [66]

    Jeyaraman MM, Al-Yousif NSH, Singh Mann A et al.. “Resveratrol for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 31978258 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
67. [67]

    Gnesin F, Thuesen ACB, Kähler LKA et al.. “Metformin monotherapy for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2020). PMID: 32501595 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
68. [68]

    Madsen KS, Kähler P, Kähler LKA et al.. “Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.” The Cochrane database of systematic reviews (2019). PMID: 30998259 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
69. [69]

    Petrov MS. “DIAGNOSIS OF ENDOCRINE DISEASE: Post-pancreatitis diabetes mellitus: prime time for secondary disease.” European journal of endocrinology (2021). PMID: 33460393 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Current Evidence and Standard
70. [70]

    Lapauw B, Kaufman JM. “MANAGEMENT OF ENDOCRINE DISEASE: Rationale and current evidence for testosterone therapy in the management of obesity and its complications.” European journal of endocrinology (2020). PMID: 33105105 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Current Evidence and Standard
71. [71]

    Zaharenko L, Kalnina I, Geldnere K et al.. “Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients.” European journal of endocrinology (2016). PMID: 27609360 ↗

    L4OTHERCited in: Bottom Line, Current Evidence and Standard
72. [72]

    Raptis D, Chiotis S, Papamichalis T et al.. “Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis.” Current diabetes reports (2026). PMID: 42277362 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
73. [73]

    Costa TA, de Sousa LMT, Nogueira A et al.. “Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis.” Heart failure reviews (2026). PMID: 42249978 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
74. [74]

    Kelly M, Saluja S, Ellis HL et al.. “A systematic review and meta-analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D).” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42165377 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
75. [75]

    Dao TP, Lung WC, Yang YZ et al.. “Cardiovascular outcomes of novel SGLT2 inhibitors in patients with type 2 diabetes: a network meta-analysis of bexagliflozin, ertugliflozin and sotagliflozin.” Diabetes research and clinical practice (2026). PMID: 42086086 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
76. [76]

    Liu C, Mujahid O, Beneyto A et al.. “Sex differences in glycemic outcomes: a systematic review and meta-analysis of diabetes treatments.” BMJ open diabetes research & care (2026). PMID: 42020119 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
77. [77]

    Boccatonda A, D'Ardes D, Brighenti A et al.. “GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.” Diabetes research and clinical practice (2026). PMID: 42009258 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
78. [78]

    Marassi M, Pollis RM, Fadini GP. “Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41997798 ↗

    L1SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
79. [79]

    Zhu X, Wang X, Zhang P et al.. “Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.” Frontiers in endocrinology (2026). PMID: 41987895 ↗

    L1SR_OBSCited in: Bottom Line, Current Evidence and Standard
80. [80]

    Samson SL, Vellanki P, Blonde L et al.. “American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2023). PMID: 37150579 ↗

    L1OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
81. [81]

    Frid AH, Kreugel G, Grassi G et al.. “New Insulin Delivery Recommendations.” Mayo Clinic proceedings (2016). PMID: 27594187 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
82. [82]

    Jun JE, Oh DH, Jeong IK et al.. “Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses.” Frontiers in endocrinology (2026). PMID: 42388875 ↗

    L2RCTCited in: Bottom Line, Current Evidence and Standard
83. [83]

    Bailey CJ. “Metformin: historical overview.” Diabetologia (2017). PMID: 28776081 ↗

    L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
84. [84]

    Sanchez-Rangel E, Inzucchi SE. “Metformin: clinical use in type 2 diabetes.” Diabetologia (2017). PMID: 28770321 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
85. [85]

    Htoo PT, Tesfaye H, Schneeweiss S et al.. “Effectiveness and safety of empagliflozin: final results from the EMPRISE study.” Diabetologia (2024). PMID: 38509341 ↗

    L2OTHERCited in: Bottom Line, Current Evidence and Standard
86. [86]

    LaMoia TE, Shulman GI. “Cellular and Molecular Mechanisms of Metformin Action.” Endocrine reviews (2021). PMID: 32897388 ↗

    L5REVIEW_NARRATIVECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
87. [87]

    Reinhart M, Puil L, Salzwedel DM et al.. “First-line diuretics versus other classes of antihypertensive drugs for hypertension.” The Cochrane database of systematic reviews (2023). PMID: 37439548 ↗

    L1REVIEW_NARRATIVECited in: Bottom Line, Current Evidence and Standard
88. [88]

    Umpierrez GE, Smiley D, Zisman A et al.. “Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).” Diabetes care (2007). PMID: 17513708 ↗

    L1RCTCited in: Background: Evolution of Treatment
89. [89]

    DeFronzo RA, Lewin A, Patel S et al.. “Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.” Diabetes care (2015). PMID: 25583754 ↗

    L1RCTCited in: Background: Evolution of Treatment
90. [90]

    Van Raalte DH, van Genugten RE, Eliasson B et al.. “The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.” European journal of endocrinology (2014). PMID: 24421302 ↗

    L1RCTCited in: Background: Evolution of Treatment
91. [91]

    Reynolds RM, Labad J, Sears AV et al.. “Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh Type 2 Diabetes Study.” European journal of endocrinology (2012). PMID: 22408122 ↗

    L3RCTCited in: Background: Evolution of Treatment
92. [92]

    Gerstein HC, Miller ME, Byington RP et al.. “Effects of intensive glucose lowering in type 2 diabetes.” The New England journal of medicine (2008). PMID: 18539917 ↗

    L1RCTCited in: Background: Evolution of Treatment
93. [93]

    Casteràs A, Zafon C, Ciudin A et al.. “Are levothyroxine requirements lower in thyroidectomized diabetic patients on metformin treatment?” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23758637 ↗

    L4OTHERCited in: Background: Evolution of Treatment
94. [94]

    Brophy S, Brunt H, Davies H et al.. “Interventions for latent autoimmune diabetes (LADA) in adults.” The Cochrane database of systematic reviews (2007). PMID: 17636829 ↗

    L1SR_OBSCited in: Background: Evolution of Treatment
95. [95]

    Dietsche KB, Magge SN, Dixon SA et al.. “Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37967247 ↗

    L2RCTCited in: Current Evidence and Standard, On the Horizon
96. [96]

    Frias JP, Bonora E, Nevarez Ruiz L et al.. “Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11).” Diabetes care (2021). PMID: 33397768 ↗

    L1RCTCited in: Current Evidence and Standard
97. [97]

    Hartman ML, Sanyal AJ, Loomba R et al.. “Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.” Diabetes care (2020). PMID: 32291277 ↗

    L1RCTCited in: Current Evidence and Standard
98. [98]

    Heerspink HJL, Sattar N, Pavo I et al.. “Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.” The lancet. Diabetes & endocrinology (2022). PMID: 36152639 ↗

    L1RCTCited in: Current Evidence and Standard, Applicability and Caveats
99. [99]

    Laffel LM, Danne T, Klingensmith GJ et al.. “Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.” The lancet. Diabetes & endocrinology (2023). PMID: 36738751 ↗

    L1RCTCited in: Current Evidence and Standard, On the Horizon
100. [100]

     Hsiao YY, Chen YY, Kuo MJ et al.. “SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39998428 ↗

     L2COHORTCited in: Current Evidence and Standard
101. [101]

     le Roux CW, Astrup A, Fujioka K et al.. “3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.” Lancet (London, England) (2017). PMID: 28237263 ↗

     L1RCTCited in: Current Evidence and Standard
102. [102]

     Frias JP, Nauck MA, Van J et al.. “Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.” Lancet (London, England) (2018). PMID: 30293770 ↗

     L1RCTCited in: Current Evidence and Standard
103. [103]

     Nicholls SJ, Pavo I, Bhatt DL et al.. “Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 41406444 ↗

     L1TRIAL_NONRANDOMCited in: Current Evidence and Standard
104. [104]

     Rosenstock J, Bailey T, Connery L et al.. “Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.” The New England journal of medicine (2025). PMID: 40548694 ↗

     L2TRIAL_NONRANDOMCited in: Current Evidence and Standard
105. [105]

     Davies MJ, Aroda VR, Rosenstock J et al.. “Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.” Lancet (London, England) (2026). PMID: 42259337 ↗

     L1RCTCited in: Current Evidence and Standard
106. [106]

     Bajaj HS, Welch M, Shah P et al.. “Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.” Lancet (London, England) (2026). PMID: 42250575 ↗

     L1RCTCited in: Current Evidence and Standard
107. [107]

     Florez JC. “The pharmacogenetics of metformin.” Diabetologia (2017). PMID: 28770331 ↗

     L5REVIEW_NARRATIVECited in: Current Evidence and Standard
108. [108]

     Schwartz AV. “Diabetes, bone and glucose-lowering agents: clinical outcomes.” Diabetologia (2017). PMID: 28451714 ↗

     L5REVIEW_NARRATIVECited in: Current Evidence and Standard
109. [109]

     Rigato M, Avogaro A, Vigili de Kreutzenberg S et al.. “Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32271381 ↗

     L1SR_OBSCited in: Applicability and Caveats
110. [110]

     Pop-Busui R, Rosin SP, Butera NM et al.. “Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.” Diabetes care (2025). PMID: 40986645 ↗

     L2RCTCited in: Applicability and Caveats
111. [111]

     Nahra R, Wang T, Gadde KM et al.. “Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.” Diabetes care (2021). PMID: 34016612 ↗

     L1RCTCited in: Applicability and Caveats
112. [112]

     Santilli F, Simeone PG, Guagnano MT et al.. “Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.” Diabetes care (2017). PMID: 28912305 ↗

     L1RCTCited in: Applicability and Caveats
113. [113]

     . “Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk.” Diabetes care (2016). PMID: 27208320 ↗

     L1RCTCited in: Applicability and Caveats
114. [114]

     Qaseem A, Obley AJ, Shamliyan T et al.. “Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.” Annals of internal medicine (2024). PMID: 38639546 ↗

     L1GUIDELINECited in: Applicability and Caveats, On the Horizon
115. [115]

     Frías JP, Guja C, Hardy E et al.. “Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.” The lancet. Diabetes & endocrinology (2016). PMID: 27651331 ↗

     L1RCTCited in: Applicability and Caveats
116. [116]

     Del Prato S, Kahn SE, Pavo I et al.. “Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.” Lancet (London, England) (2021). PMID: 34672967 ↗

     L2TRIAL_NONRANDOMCited in: Applicability and Caveats
117. [117]

     Svanström H, Ueda P, Melbye M et al.. “Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.” The lancet. Diabetes & endocrinology (2018). PMID: 30527909 ↗

     L2COHORTCited in: Applicability and Caveats
118. [118]

     Wang HH, Lin SH, Hung SY et al.. “Renal Protective Effect of Metformin in Type 2 Diabetes Patients.” The Journal of clinical endocrinology and metabolism (2025). PMID: 38986038 ↗

     L3OTHERCited in: Applicability and Caveats
119. [119]

     Nabrdalik K, Kwiendacz H, Irlik K et al.. “Machine Learning Identifies Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38330228 ↗

     L3OTHERCited in: Applicability and Caveats
120. [120]

     Croyal M, Saulnier PJ, Aguesse A et al.. “Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32301490 ↗

     L2OTHERCited in: Applicability and Caveats
121. [121]

     Ostrominski JW, Claggett BL, Miao ZM et al.. “Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease.” Diabetes care (2025). PMID: 40019856 ↗

     L1OTHERCited in: Applicability and Caveats
122. [122]

     Lalau JD, Kajbaf F, Bennis Y et al.. “Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4.” Diabetes care (2018). PMID: 29305402 ↗

     L2OTHERCited in: Applicability and Caveats
123. [123]

     Kwon S, Kim YC, Park JY et al.. “The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.” Diabetes care (2020). PMID: 32132005 ↗

     L3OTHERCited in: Applicability and Caveats
124. [124]

     Liaw J, Harhay M, Setoguchi S et al.. “Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020.” Diabetes care (2022). PMID: 35984049 ↗

     L2OTHERCited in: Applicability and Caveats
125. [125]

     Caparrotta TM, Blackbourn LAK, McGurnaghan SJ et al.. “Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.” Diabetes care (2020). PMID: 32581068 ↗

     L5OTHERCited in: Applicability and Caveats
126. [126]

     El-Damanawi R, Stanley IK, Staatz C et al.. “Metformin for preventing the progression of chronic kidney disease.” The Cochrane database of systematic reviews (2024). PMID: 38837240 ↗

     L1SR_OBSCited in: Applicability and Caveats, On the Horizon
127. [127]

     Areosa Sastre A, Vernooij RW, González-Colaço Harmand M et al.. “Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia.” The Cochrane database of systematic reviews (2017). PMID: 28617932 ↗

     L1SR_OBSCited in: Applicability and Caveats
128. [128]

     de Boer IH, Khunti K, Sadusky T et al.. “Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).” Diabetes care (2022). PMID: 36189689 ↗

     L1REVIEW_NARRATIVECited in: Applicability and Caveats
129. [129]

     Standl E, Schnell O, McGuire DK et al.. “Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.” The lancet. Diabetes & endocrinology (2017). PMID: 28131656 ↗

     L5REVIEW_NARRATIVECited in: Applicability and Caveats
130. [130]

     Xie C, White JB, Huang W et al.. “Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes.” Diabetes (2026). PMID: 41591292 ↗

     L1RCTCited in: Applicability and Caveats
131. [131]

     Pearson ER, Del Prato S, Pavo I et al.. “Predictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4.” Diabetes (2025). PMID: 40633089 ↗

     L2RCTCited in: Applicability and Caveats
132. [132]

     Mochizuki K, Fuchigami A, Hirose T et al.. “Impact of baseline alanine aminotransferase levels on the efficacy of dapagliflozin and sitagliptin: Latent class analysis from the DIVERSITY-CVR study.” Diabetes, obesity & metabolism (2025). PMID: 40563136 ↗

     L2RCTCited in: Applicability and Caveats
133. [133]

     Roos PR, van den Burg EL, Schoonakker MP et al.. “Fasting-mimicking diet in type 2 diabetes reduces myocardial triglyceride content: A 12-month randomised controlled trial.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2025). PMID: 39934050 ↗

     L1RCTCited in: Applicability and Caveats
134. [134]

     Lu J, Sun S, Shang X et al.. “Genetic Evidence for the Benefits and Risks of Glucose-Lowering Drugs on Cardiovascular-Kidney-Metabolic Syndrome: A Drug-Target Mendelian Randomization Study.” International journal of medical sciences (2026). PMID: 42328113 ↗

     L2SR_OBSCited in: Applicability and Caveats
135. [135]

     Shabu A, Naqvi SM, Hesari F et al.. “Effect of Oral Hypoglycaemic Agents on Carotid Artery Intima-Media Thickness in Patients With Cardiovascular Disease and/or Diabetes-A Systematic Review.” Endocrinology, diabetes & metabolism (2025). PMID: 41267359 ↗

     L1SR_OBSCited in: Applicability and Caveats
136. [136]

     Eleftheriadou A, Riley D, Zhao SS et al.. “Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.” Diabetologia (2024). PMID: 38584180 ↗

     L3OTHERCited in: Applicability and Caveats
137. [137]

     Cavalcante PN, Barreto J, Kimura-Medorima ST et al.. “Dapagliflozin reduces the white coat effect on systolic blood pressure of patients with type 2 diabetes: a post-hoc analysis from the ADDENDA-BHS 2 trial.” Current medical research and opinion (2024). PMID: 39706688 ↗

     L2RCTCited in: Applicability and Caveats
138. [138]

     Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2025). PMID: 41365423 ↗

     L1GUIDELINECited in: Applicability and Caveats
139. [139]

     Borooghani H, Arabi M, Kazemi Jahromi M. “Efficacy and Safety of Oral Antidiabetic Drugs in People with Diabetes and Chronic Kidney Disease: A Systematic Review.” Iranian journal of kidney diseases (2025). PMID: 42234904 ↗

     L1SR_OBSCited in: Applicability and Caveats
140. [140]

     Mather KJ, Mari A, Heise T et al.. “Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38795393 ↗

     L1RCTCited in: On the Horizon
141. [141]

     Pedersen AKN, Gormsen LC, Nielsen S et al.. “Metformin Improves the Prerequisites for FGF21 Signaling in Patients With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37776319 ↗

     L1RCTCited in: On the Horizon
142. [142]

     Simonson DC, Testa MA, Ekholm E et al.. “Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38412282 ↗

     L2RCTCited in: On the Horizon
143. [143]

     Cordiner RLM, Bedair K, Mari A et al.. “Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38267622 ↗

     L2RCTCited in: On the Horizon
144. [144]

     Zeitler P, Galindo RJ, Davies MJ et al.. “Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.” Diabetes care (2024). PMID: 38639997 ↗

     L2RCTCited in: On the Horizon
145. [145]

     Latva-Rasku A, Rebelos E, Tuisku J et al.. “SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study.” Diabetes care (2024). PMID: 38941156 ↗

     L1RCTCited in: On the Horizon
146. [146]

     Rasouli N, Younes N, Ghosh A et al.. “Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.” Diabetes care (2024). PMID: 38211595 ↗

     L1RCTCited in: On the Horizon
147. [147]

     Chen ZZ, Lu C, Dreyfuss JM et al.. “Circulating Metabolite Biomarkers of Glycemic Control in Youth-Onset Type 2 Diabetes.” Diabetes care (2024). PMID: 38935559 ↗

     L2RCTCited in: On the Horizon
148. [148]

     Wang H, Cordiner RLM, Huang Y et al.. “Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study.” Diabetes care (2023). PMID: 36944118 ↗

     L2RCTCited in: On the Horizon
149. [149]

     Cengiz E, Danne T, Ahmad T et al.. “International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes.” Hormone research in paediatrics (2025). PMID: 39884261 ↗

     L1GUIDELINECited in: On the Horizon
150. [150]

     Hansen LS, Gasbjerg LS, Brønden A et al.. “The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.” European journal of endocrinology (2024). PMID: 39049802 ↗

     L1RCTCited in: On the Horizon
151. [151]

     Małecki MT, Batterham RL, Sattar N et al.. “Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.” Diabetes care (2023). PMID: 37824793 ↗

     L2TRIAL_NONRANDOMCited in: On the Horizon
152. [152]

     Zhang L, Zhang Y, Shen S et al.. “Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.” The lancet. Diabetes & endocrinology (2023). PMID: 37414069 ↗

     L1RCTCited in: On the Horizon
153. [153]

     Sandforth A, von Schwartzenberg RJ, Arreola EV et al.. “Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).” The lancet. Diabetes & endocrinology (2023). PMID: 37769677 ↗

     L2RCTCited in: On the Horizon
154. [154]

     Feig DS, Sanchez JJ, Murphy KE et al.. “Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial.” The lancet. Diabetes & endocrinology (2023). PMID: 36746160 ↗

     L1RCTCited in: On the Horizon
155. [155]

     Adler AI, Coleman RL, Leal J et al.. “Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).” Lancet (London, England) (2024). PMID: 38772405 ↗

     L1RCTCited in: On the Horizon
156. [156]

     Nadeau KJ, Arslanian SA, Bacha F et al.. “Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial.” Diabetologia (2024). PMID: 39706874 ↗

     L2RCTCited in: On the Horizon
157. [157]

     Moens de Hase E, Neyrinck AM, Rodriguez J et al.. “Impact of metformin and Dysosmobacter welbionis on diet-induced obesity and diabetes: from clinical observation to preclinical intervention.” Diabetologia (2023). PMID: 37897566 ↗

     L2RCTCited in: On the Horizon
158. [158]

     Garrib A, Kivuyo S, Bates K et al.. “Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial.” Diabetologia (2023). PMID: 37460828 ↗

     L1RCTCited in: On the Horizon
159. [159]

     Xie C, Iroga P, Bound MJ et al.. “Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.” Diabetologia (2024). PMID: 38561463 ↗

     L1RCTCited in: On the Horizon
160. [160]

     Davidsen L, Jensen MH, Cook ME et al.. “Metformin treatment is associated with reduced risk of hypoglycaemia, major adverse cardiovascular events, and all-cause mortality in patients with post-pancreatitis diabetes mellitus: a nationwide cohort study.” European journal of endocrinology (2024). PMID: 38134412 ↗

     L2COHORTCited in: On the Horizon
161. [161]

     Krishnan A, Schneider CV, Hadi Y et al.. “Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.” Diabetologia (2023). PMID: 38117293 ↗

     L2COHORTCited in: On the Horizon
162. [162]

     Li Z, Lin C, Cai X et al.. “Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials.” Alzheimer's research & therapy (2024). PMID: 39716328 ↗

     L1SR_MA_RCTCited in: On the Horizon
163. [163]

     Hitt TA, Hannon TS, Magge SN. “Approach to the Patient: Youth-Onset Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37584397 ↗

     L5OTHERCited in: On the Horizon
164. [164]

     Chung ST, Davis F, Patel T et al.. “Reevaluating First-line Therapies in Youth-Onset Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37624230 ↗

     L5OTHERCited in: On the Horizon
165. [165]

     Flowers E, Aouizerat BE, Kanaya AM et al.. “MicroRNAs Associated With Incident Diabetes in the Diabetes Prevention Program.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36477577 ↗

     L2OTHERCited in: On the Horizon
166. [166]

     Yu OHY, Suissa S. “Metformin and Cancer: Solutions to a Real-World Evidence Failure.” Diabetes care (2023). PMID: 37185680 ↗

     L5REVIEW_NARRATIVECited in: On the Horizon
167. [167]

     Bao Y, Hu Y, Shi M et al.. “SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.” Diabetes, obesity & metabolism (2024). PMID: 39639835 ↗

     L1SR_OBSCited in: On the Horizon
168. [168]

     Shabil M, Khatib MN, Ballal S et al.. “Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis.” BMC endocrine disorders (2024). PMID: 39551761 ↗

     L1SR_OBSCited in: On the Horizon
169. [169]

     Gunabalasingam S, Kyrka A, Hopkins L et al.. “Interventions in women with type 2 diabetes mellitus in the pre-pregnancy, pregnancy and postpartum periods to optimise care and health outcomes: A systematic review.” Diabetic medicine : a journal of the British Diabetic Association (2024). PMID: 39527377 ↗

     L1SR_OBSCited in: On the Horizon
170. [170]

     Xie Y, Bowe B, Xian H et al.. “Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records.” The lancet. Diabetes & endocrinology (2023). PMID: 37499675 ↗

     L2OTHERCited in: On the Horizon
171. [171]

     Munshi MN, Venditti EM, Tjaden AH et al.. “Long-term impact of Diabetes Prevention Program interventions on walking endurance.” Frontiers in public health (2024). PMID: 39744353 ↗

     L1RCTCited in: On the Horizon
172. [172]

     Takahashi A, Nomoto H, Yokoyama H et al.. “Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).” Diabetes, obesity & metabolism (2024). PMID: 39726204 ↗

     L1RCTCited in: On the Horizon
173. [173]

     Rosell-Díaz M, Fernández-Real JM. “Metformin, Cognitive Function, and Changes in the Gut Microbiome.” Endocrine reviews (2024). PMID: 37603460 ↗

     L5REVIEW_NARRATIVECited in: On the Horizon